Navigation Links
AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
Date:9/25/2008

AFFITOME technology will also be able to exert a positive influence on other human rogue proteins - such as lipid metabolism enzymes. In line with our strategy of developing medicines for diseases with urgent medical need and attractive market potential, one of our next product candidates can deliver effective results in the treatment of atherosclerosis."

Michael Motschmann, Senior Fund Manager at MIG Fonds, comments on business developments at AFFiRiS GmbH: "In an amazingly short period of time, the company has developed two vaccines against Alzheimer's disease from the initial idea to the first phase I clinical trial, thus underlining the effectiveness of its highly promising business model. We have every reason to believe that these vaccines make interesting product candidates and expect comparable developments to follow in other indications. This progress alone prompted us to make another substantial investment. What's more, the AFFITOME technology behind the development of these vaccines represents an almost inestimable value, which can make the company a very attractive licenser for major pharmaceutical companies."

About AFFiRiS GmbH (as at September 2008):

AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other diseases that urgently require a medical solution. The company has established platform technologies and registered the corresponding patent families. The first patents have already been issued. It employs 35 highly qualified members of staff on 600msquared of rented laboratory facilities at the Campus Vienna Biocenter (http://www.affiris.com).

About MIG-Fonds:

The participation of MIG Verwaltungs AG in Affiris GmbH represents the continuation of a tried-and-tested approach. Investment is only made in selected companies in Germany and Austria after their viability has been thoroughly audited. Its innovative, hig
'/>"/>

SOURCE AFFiRiS GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Gerresheimer Further Increases its Sales and Earnings Power
2. OncoGenex increases economic interest in lead cancer drug OGX-011
3. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
4. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
5. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
6. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
7. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
8. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
9. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
10. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
11. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... United Kingdom -based Lab M Holdings, ... and diagnostic systems. Lab M was ... provider of microbial testing and diagnostic products for the ... company currently sells into more than 70 countries worldwide, ...
(Date:8/27/2015)... DIEGO , Aug. 27, 2015 HUYA ... annual meeting of the Japan Society of HTLV-1, held ... Institute Auditorium. The purpose of the Society is to ... as the development of medical technology and research related ... and welfare. "HUYA is proud to support ...
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... Vical Incorporated,(Nasdaq: VICL ) presentation at the ... at 1 p.m. Eastern Daylight Time, will be ... page at http://www.vical.com ., About Vical, ... on its,patented DNA delivery technologies for the prevention ...
... - Oncentra(R) RT Viewer* Officially to Launch ... ASTRO 2008, Boston, USA, September,21-24, Nucletron, a ... release of Oncentra RT Viewer. This unique innovation,in ... review,radiotherapy plans that are generated with a wide ...
... significant partial onset seizure reduction, proven ... - Keppra XR(TM) is ... press release, regulated information:,UCB announced today that the U.S. Food ... for use as,an add-on to other antiepileptic treatments for people ...
Cached Biology Technology:Vical to Present at UBS Global Life Sciences Conference 2Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy 2Video: Keppra XR(TM) Approved in the U.S. 2Video: Keppra XR(TM) Approved in the U.S. 3Video: Keppra XR(TM) Approved in the U.S. 4
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Va.Rear Adm. Matthew Klunder, the chief of naval research, told ... science and technology (S&T) conference this week that he intends ... academia together on a quarterly basis, starting in 2013, to ... conference every two years, which is phenomenal and very valuableand ...
... , BioFrontiers Institute scientists at the University of Colorado Boulder, ... anti-cancer drug development that is sitting at the ends of ... collaborated to find a patch of amino acids that, if ... this location, may prevent cancerous cells from reproducing. The amino ...
... BEDFORD, Mass., Sept. 21, 2012 Aware, Inc. (NASDAQ: ... completed the sale (as previously announced on August 23, ... Delta, LLC for US $16,000,000.00.  The patents and patent ... of our patent management operation,s efforts to sell and/or ...
Cached Biology News:In an uncertain world, Navy needs science and technology collaboration, chief says 2CU-Boulder researchers uncover new target for cancer research 2Aware Announces Closing Of Sale Of Selected Patents 2Aware Announces Closing Of Sale Of Selected Patents 3
... Peptide Antigen Design , Customer Peptide Synthesis , 20 ... 90% , 20 mg will return to customer for ... x 2 , Maintenance 102 days/each ... Immunizations/Boost injections x5 /each , Test bleed ...
Request Info...
... Immunogen: Synthetic peptide derived from ... junctophilin-1. Specificity: Specific for the ... controls: mouse brain and skeletal muscle ... muscle tissues). Applications: Western blotting ...
... R&D Systems adds two new Stem Cell ... stem cell products. The Human Embryonic Stem ... contains the antibodies against: alkaline phosphatase, Nanog, ... Stem Cell Marker Antibody Panel Plus (Catalog ...
Biology Products: